TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Anas Younes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.